Tracking the uptake of outcomes of hepatitis B virus testing using laboratory data in Victoria, 2011-16: a population-level cohort study.


Journal

Sexual health
ISSN: 1449-8987
Titre abrégé: Sex Health
Pays: Australia
ID NLM: 101242667

Informations de publication

Date de publication:
08 2019
Historique:
received: 22 05 2018
accepted: 14 03 2019
pubmed: 2 7 2019
medline: 22 9 2020
entrez: 2 7 2019
Statut: ppublish

Résumé

Background A priority area in the 2016 Victorian Hepatitis B Strategy is to increase diagnostic testing. This study describes hepatitis B testing and positivity trends in Victoria between 2011 and 2016 using data from a national laboratory sentinel surveillance system. Line-listed diagnostic and monitoring hepatitis B testing data among Victorian individuals were collated from six laboratories participating in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) of sexually transmissible infections and blood-borne viruses. Diagnostic tests included hepatitis B surface antigen (HBsAg)-only tests and guideline-based hepatitis B tests (defined as a single test event for HBsAg, hepatitis B surface antibody and hepatitis B core antibody). Using available data, the outcomes of testing and/or infection were further classified. Measures reported include the total number of HBsAg and guideline-based tests conducted and the proportion positive, classified as either HBsAg positive or chronic hepatitis B infection. The number of HBsAg tests decreased slightly each year between 2011 and 2016 (from 91043 in 2011 to 79664 in 2016; P < 0.001), whereas the number of guideline-based hepatitis B tests increased (from 8732 in 2011 to 16085 in 2016; P <0.001). The proportion of individuals classified as having chronic infection decreased from 25% in 2011 to 7% in 2016, whereas the proportion classified as susceptible and immune due to vaccination increased (from 29% to 39%, and from 27% to 34%, respectively; P < 0.001). The study findings indicate an increased uptake of guideline-based hepatitis B testing. The ongoing collection of testing data can help monitor progress towards implementation of the Victorian Hepatitis B Strategy.

Identifiants

pubmed: 31256771
pii: SH18102
doi: 10.1071/SH18102
doi:

Substances chimiques

Hepatitis B Antibodies 0
Hepatitis B Core Antigens 0
Hepatitis B Surface Antigens 0
Hepatitis B Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

358-366

Auteurs

Caroline van Gemert (C)

Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Department of Epidemiology and Preventative Medicine, Monash University, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia; and Corresponding author. Email: caroline.vangemert@burnet.edu.au.

Wayne Dimech (W)

NRL, 4th Floor, Healy Building, 41 Victoria Parade, Fitzroy, Vic. 3065, Australia.

Mark Stoove (M)

Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Department of Epidemiology and Preventative Medicine, Monash University, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.

Rebecca Guy (R)

The Kirby Institute, UNSW Australia, Wallace Wurth Building, Sydney, NSW 2052, Australia.

Jess Howell (J)

Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Department of Medicine, The University of Melbourne, Vic. 3010, Australia.

Scott Bowden (S)

Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Vic. 3000, Australia.

Suellen Nicholson (S)

Victorian Infectious Diseases Reference Laboratory, Peter Doherty Institute for Infection and Immunity, Vic. 3000, Australia.

Stella Pendle (S)

Australian Clinical Labs, 14 Lexington Drive, Bella Vista, NSW 2153, Australia.

Basil Donovan (B)

The Kirby Institute, UNSW Australia, Wallace Wurth Building, Sydney, NSW 2052, Australia.

Margaret Hellard (M)

Burnet Institute, 85 Commercial Road, Melbourne, Vic. 3004, Australia; and Department of Epidemiology and Preventative Medicine, Monash University, Alfred Hospital, Commercial Road, Melbourne, Vic. 3004, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH